Subtle Medical Expands AI Imaging Leadership With Tanenbaum
Menlo Park, California, August 20, 2026 Subtle Medical, a provider of AI-powered medical imaging solutions, has appointed Lawrence N....
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Menlo Park, California, August 20, 2026 Subtle Medical, a provider of AI-powered medical imaging solutions, has appointed Lawrence N....
MENLO PARK, Calif., June 10, 2026 Subtle Medical has received U.S. FDA clearance for SubtleHDâ„¢(CT), a new artificial intelligence-powered...
